L4 ANSWER 1 OF 2 ZCA COPYRIGHT 2007 ACS on STN
AN 142:134587 ZCA Full-text
TI Preparation of substituted 4,5,6,7-tetrahydropyrazolo[3,4-c]pyridines and their compositions useful in the treatment of cancer
IN Halley, Franck; Bouchard, Herve; Gauzy, Lazo Laurence; Baudoin, Bernard; Souaille, Catherine; Damiano, Teresa; Thompson, Fabienne
PA Aventis Pharma Sa, Fr.
SO Fr. Demande, 61 pp.
CODEN: FRXXBL
DT Patent
LA French
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2857363	A1	20050114	FR 2003-8442	20030710
	AU 2004256945	A1	20050127	AU 2004-256945	20040708
	CA 2532122	A1	20050127	CA 2004-2532122	20040708
	WO 2005007653	A2	20050127	WO 2004-FR1778	20040708 <--
	WO 2005007653	A3	20050324		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1646632	A2	20060419	EP 2004-767613	20040708
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	BR 2004012411	A	20060822	BR 2004-12411	20040708
	CN 1823066	A	20060823	CN 2004-80019823	20040708
	US 2005096345	A1	20050505	US 2004-888611	20040709
	US 7109340	B2	20060919		
	US 2006199837	A1	20060907	US 2006-419794	20060523
PRAI	FR 2003-8441	A	20030710		
	FR 2003-8442	A	20030710		
	WO 2004-FR1778	W	20040708		
	US 2004-888611	A3	20040709		

OS MARPAT 142:134587
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Tetrahydropyrazolo[3,4-c]pyridines [I; X = a bond, CH2, CO, SO2, CONH, COO; R1 = (un)substituted cyclo/alkyl, heterocyclyl, hetero/aryl; R2 = H, (un)substituted cyclo/alkyl, hetero/aryl, heterocyclyl, etc.; and their racemates, stereoisomers and salts], e.g. II, were prepared as kinase inhibitors, in particular Tie2 and KDR inhibitors. Libraries of amides, sulfonamides, amines ans ureas are generated. For instance, reacting III (preparation given) with 2-phenylethyl isocyanate gave urea IV. II exhibited 88.1% and 96.7% inhibition of the Tie2 and KDR activity. I are useful for treating cancer (no data).
RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT